Physician profile
Laszlo Szollas
NPI 1790880003
$3,184.27
in general payments reported to CMS, 2019-2025
25 companies · $629 in 2025
The $629 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $874 · 2021: $541 · 2022: $188 · 2023: $459 · 2024: $369 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $994.00 | 2020-2025 | Cascadia Interbody System, Inspace |
| Boston Scientific Corporation | $605.50 | 2019-2025 | Infinion 16, Wavewriter Alpha Prime 16, Infinion 16 |
| Medtronic, INC. | $326.74 | 2023 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $188.82 | 2020-2025 | Belbuca |
| Endo Pharmaceuticals INC. | $181.23 | 2020-2022 | |
| Nevro Corp. | $173.37 | 2024 | Senza |
| Ermi LLC | $81.11 | 2020-2025 | |
| Globus Medical, INC. | $78.16 | 2025 | Senza |
| Depuy Synthes Sales INC. | $75.11 | 2019-2025 | Orthovisc, Monovisc |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.38 | 2024-2025 | Relistor |
| Pfizer INC. | $52.60 | 2019-2021 | |
| Si-Bone, INC. | $45.73 | 2021 | |
| Novus Surgical Solutions LLC | $42.83 | 2020 | |
| Horizon Therapeutics Plc | $38.17 | 2020-2021 | |
| Bioventus LLC | $35.36 | 2024-2025 | Durolane |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $28.00 | 2020-2023 | Euflexxa |
| Kaleo, INC. | $25.46 | 2019 | |
| Organogenesis INC. | $22.59 | 2023 | Puraply |
| Pacira Therapeutics, INC. | $20.77 | 2021 | |
| Omeros Corporation | $18.76 | 2021 | |
| Electronic Waveform Lab, INC. | $17.13 | 2025 | |
| Avanos Medical | $16.94 | 2022 | |
| Daiichi Sankyo INC. | $16.88 | 2019 | |
| Smith+Nephew, INC. | $13.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laszlo Szollas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.